Watchlist · 79/100Sep 8, 1:03 PM EDT
Amgen and AstraZeneca's Combination Therapy Boosts Survival in Late-Stage Lung Cancer Trial
AMGNAZN
Amgen and AstraZeneca announced that their drug combination of Imdelltra and Imfinzi extended overall survival in a late-stage trial for extensive-stage small cell lung cancer. This positive interim data could strengthen the companies' positions in the competi…
- ▹Late-stage OS benefit for Imdelltra+Imfinzi combo in ES-SCLC, a high-unmet-need setting, supports regulatory filing and label expansion.
- ▹Combines Amgen's bispecific T-cell engager platform with AstraZeneca's PD-L1 franchise, but commercial impact is still pre-approval for this indication.
Neutral · 55/100Sep 8, 9:27 AM EDT
Inhibrx's INBRX-106 Tops Keytruda in Phase 2 Head and Neck Cancer Trial
INBXMRK
Inhibrx Biosciences announced that its experimental therapy INBRX-106 outperformed Merck's Keytruda (pembrolizumab) in a Phase 2 trial for head and neck cancer. The positive data sent INBX shares higher in premarket trading. This suggests INBRX-106 could becom…
- ▹Phase 2 data shows INBRX-106 outperforming Keytruda in head and neck cancer, but no regulatory designations or accelerated path mentioned.
- ▹Single-asset clinical-stage company with no commercial revenue, limited manufacturing details, and potential dilution risk.
Neutral · 50/100Sep 8, 12:28 PM EDT
RBC Downgrades Biohaven to Sector Perform Following SK Biopharma Licensing Deal
BHVN
RBC Capital Markets downgraded Biohaven (BHVN) to Sector Perform from Outperform, citing the company's recent licensing deal with South Korea's SK Biopharmaceuticals as making the stock less attractive. The analyst acknowledged the deal was strategically corre…
- ▹RBC downgrade to Sector Perform reflects reduced appeal after SK Biopharma licensing deal
- ▹Clinical-stage biotech with no commercial revenue and limited near-term catalysts
High Risk · 47/100Sep 8, 1:54 PM EDT
Beam Therapeutics Stock Falls 10% on Updated BEAM-302 Trial Data
BEAM
Beam Therapeutics released updated Phase 1/2 data for BEAM-302, its gene-editing therapy for alpha-1 antitrypsin deficiency, as of a June 24 cutoff. The stock dropped over 10% on the news, indicating investor disappointment with the results. This matters for i…
- ▹Updated Phase 1/2 data for BEAM-302 triggered a >10% stock drop, signaling investor disappointment and uncertainty.
- ▹Single-asset clinical-stage gene-editing therapy with no commercial revenue and limited regulatory clarity.
High Risk · 42/100Sep 8, 9:12 AM EDT
PDS Biotech Secures $22.55M PIPE to Fuel Late-Stage Push in Colorectal Cancer
PDSB
PDS Biotechnology raised up to $22.55 million in a PIPE financing led by Nant Capital, with existing investors also participating. The funds will be used to advance PDS0301 (PDS01ADC/NHS-IL12) into late-stage clinical development for metastatic colorectal canc…
- ▹PIPE financing extends runway but signals dilution risk and cash burn
- ▹Single-asset late-stage program with no commercial revenue or regulatory milestones
High Risk · 40/100Sep 8, 10:26 AM EDT
Amgen Shares Plunge 8% as Novartis Heart Drug Trial Fails, BMO Downgrades
AMGNNVSIONSARWR
Novartis announced a late-stage trial failure for its heart disease therapy developed with Ionis Pharmaceuticals, causing Amgen shares to drop over 8% in their worst single-day decline since 2016. BMO Capital Markets subsequently downgraded Amgen, heightening…
- ▹Novartis late-stage trial setback for heart therapy impacts Amgen sentiment and triggers BMO downgrade
- ▹Amgen's 8% drop reflects competitive/readthrough risk, not direct regulatory action